Afatinib: First Global Approval

被引:351
作者
Dungo, Rosselle T. [1 ]
Keating, Gillian M. [2 ]
机构
[1] Adis R&D Insight, Auckland 0754, New Zealand
[2] Adis Int Ltd, Auckland 10, New Zealand
关键词
CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; ERBB FAMILY BLOCKER; I DOSE-ESCALATION; BIBW; 2992; PHASE-I; OPEN-LABEL; TYROSINE KINASE; ORAL TREATMENT; TRIAL;
D O I
10.1007/s40265-013-0111-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer. Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation. It also inhibits transphosphorylation of HER3. Oral afatinib (Gilotrif (TM)) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test. Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-positive NSCLC. In addition, the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif(A (R))) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor na < ve. Afatinib is also under regulatory review in Canada, Japan and other Asian countries. This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.
引用
收藏
页码:1503 / 1515
页数:13
相关论文
共 55 条
[21]  
Bouche O, 2011, ANTICANCER RES, V31, P2271
[22]   Management of Recurrent Head and Neck Cancer Recent Progress and Future Directions [J].
Brockstein, Bruce E. .
DRUGS, 2011, 71 (12) :1551-1559
[23]   Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab [J].
Chen, Gang ;
Kronenberger, Peter ;
Teugels, Erik ;
Umelo, Ijeoma Adaku ;
De Greve, Jacques .
BMC MEDICINE, 2012, 10
[24]   Clinical perspective of afatinib in non-small cell lung cancer [J].
Chen, Xiaofeng ;
Zhu, Quan ;
Zhu, Lingjun ;
Pei, Dong ;
Liu, Yiqian ;
Yin, Yongmei ;
Schuler, Martin ;
Shu, Yongqian .
LUNG CANCER, 2013, 81 (02) :155-161
[25]  
Chu QS, 2013, J CLIN ONCOL, V31
[26]   Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu [J].
De Greve, J. ;
Teugels, E. ;
Geers, C. ;
Decoster, L. ;
Galdermans, D. ;
De Mey, J. ;
Everaert, H. ;
Umelo, I. ;
In't Veld, P. ;
Schallier, D. .
LUNG CANCER, 2012, 76 (01) :123-127
[27]  
De Greve J, 2013, J CLIN ONCOL, V31
[28]   A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. [J].
Eisenstat, D. D. ;
Nabors, L. B. ;
Mason, W. P. ;
Perry, J. R. ;
Shapiro, W. R. ;
Kavan, P. ;
Phuphanich, S. ;
Fu, Y. ;
Cong, X. J. ;
Shahidi, M. ;
Reardon, D. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29]   A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [J].
Eskens, Falm ;
Mom, C. H. ;
Planting, A. S. T. ;
Gietema, J. A. ;
Amelsberg, A. ;
Huisman, H. ;
van Doorn, L. ;
Burger, H. ;
Stopfer, P. ;
Verweij, J. ;
de Vries, Ege .
BRITISH JOURNAL OF CANCER, 2008, 98 (01) :80-85
[30]  
Geater SL, 2013, J CLIN ONCOL, V31